Results for tag: "Thromboangiitis Drug"

Thromboangiitis is a rare form of vasculitis that affects small and medium-sized arteries and veins. It is characterized by inflammation of the blood vessels, thrombosis, and the formation of aneurysms. Treatment of thromboangiitis typically involves anticoagulants, antiplatelet agents, and immunosuppressants. Cardiovascular drugs are used to treat thromboangiitis, as they can reduce inflammation, prevent clot formation, and reduce the risk of aneurysm formation. The thromboangiitis drug market is a niche market, as the disease is rare and the drugs used to treat it are specialized. The market is expected to grow in the coming years, as new treatments are developed and the number of patients increases. Some companies in the thromboangiitis drug market include Pfizer, Merck, Novartis, and Sanofi. Show Less Read more